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Abstract 
Introduction. The medical aim of translational research is to smooth the transition of 
discoveries made through basic research from the laboratory bench to their diagnostic 
or therapeutic applications for patients. These applications may be extended to current 
clinical practice and to health policies.
Aim. The converse is also important: health policies should provide a point of departure 
when identifying research priorities. Translational research poses the same ethical prob-
lems as trials with human subjects – albeit in different ways. One of the more significant 
problems is the risk for participants in trials: it is thus necessary to ensure that the risks 
to which these subjects are exposed are not out of proportion to the expected benefits.
Discussion. Translational research does not require new ethical principles, but existing 
biomedical principles need to be adjusted to the specific context. The well-being of par-
ticipants should always be the primary objective; these persons should never be consid-
ered as means for the advancement of knowledge or for the improvement of applications.
FOREWORD
Following its appointment by the Health Ministry, 
the Istituto Superiore di Sanità (ISS) has contributed, 
together with the Ministry of Education, University 
and Researach (MIUR) to the planning and creation of 
three key research infrastructures for health in Europe. 
One of these is the European Advanced Translational 
Research Infrastructure (EATRIS).
The present article is the result of the author’s coop-
eration in: 1) the planning stage prior to the establish-
ment of EATRIS; and 2) the “front door”, for ethical 
issues, of the Italian Advanced Translational Research 
Infrastructure (IATRIS), the Italian arm of EATRIS: the 
text is based on a conference given by the author to the 
Istituto Scientifico Romagnolo per lo Studio e la Cura 
dei Tumori (IRST).
WHAT IS TRANSLATIONAL RESEARCH?
Wolfgang Goethe was certainly not thinking of 
translational research when he wrote: “Knowing is 
not enough; we must apply. Willing is not enough; we 
must do”. His words nonetheless neatly encapsulate 
the essence of translational research: the transition 
from knowledge to its application.
Knowledge translation
The notion of “translation” can be applied not only 
to the field of biomedical research, but to a number of 
other fields of knowledge, and there are many ways of 
describing it: “Many terms are used to describe the pro-
cess of putting knowledge into action” [1], one particu-
larly effective one being “knowledge translation” [2].
The Canadian Institute of Health Research (CIHR) 
is one of the institutions that has examined knowledge 
translation in depth. The CIHR researchers have de-
fined it as “A dynamic and iterative process that in-
cludes synthesis, dissemination, exchange and ethically 
sound application of knowledge to improve health (…), 
provide more effective health services and products and 
strengthen the health care system” [3].
The present article refers to “translational research” in 
the biomedical setting.
The American Physiological Society has adopted a 
much-quoted definition of translational research: “The 
transfer of knowledge gained from basic research to 
new and improved methods of preventing, diagnosing, 
or treating disease, as well as the transfer of clinical in-
sights into hypotheses that can be tested and validated 
in the basic research laboratory” [4].
The issue is of primary significance: in recent years 
“the United States, Europe and Japan have seen sharp 
rises in the attrition of drugs tested in trials” [5] and 
“Most of the product failures in phase II and III trials 
are because researchers are unable to demonstrate effi-
cacy or sufficient safety”. The Food and Drug Adminis-
tration (FDA) described the problem as a “technologi-
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cal disconnection between discovery and the product 
development process” [6].
From bench to bedside. From bedside to clinical 
practice and public health
A catch phrase that is much used to indicate trans-
lational research, particularly in less strictly scientific 
contexts, is “From bench to bedside”. The translational 
researcher has been described as “someone who takes 
something from basic research to a patient and meas-
ures an endpoint in a patient” [7]. 
The steps along this path have been variously clas-
sified. Woolf, for instance, identifies T1 as the phase 
in which new knowledge relating to the mechanisms of 
disease gathered in the laboratory is transformed into 
the development of new procedures for diagnosis, ther-
apy and prevention, and includes their initial trials in 
humans; T2 is the phase in which the results of those 
clinical trials are translated into everyday clinical prac-
tice and taken into account when health decisions are 
made [8].
Fiscella and co-authors propose additional subdivi-
sions: they suggest that preclinical research should 
be divided into: long-term preclinical translational re-
search, of 5-10 years, and short-term preclinical transla-
tional research, of less than 5 years. For applied clinical 
research (ACR) they propose a subdivision into: clinical 
ACR, patient ACR, organisational ACR and communi-
ty-focused ACR [9].
Translational research can thus be transferred not only 
“from bench to bedside”, but also from the bedside to 
clinical practice, to general policies and, finally, to pub-
lic health. Public health policies should be based, among 
other things, on evidence generated by clinical practice: 
“Public health is de facto a translational industry that 
concerns itself with bringing about improvements to the 
health of populations through the best science” [10].
POSSIBLE STRATEGIES TO PROMOTE
TRANSLATIONAL RESEARCH
Concerted action by several disciplines
Although the objective of translational research is to 
reduce the interval between a scientific discovery and 
its application, the process is not brief and it involves 
numerous areas of competence.
According to Abani and Parakken, “structures that 
are needed to move an idea from its conceptual stage to 
early clinical development” are: “intellectual property, 
scientific advances, early clinical development, licens-
ing to industry spin-off, financial returns, funding for 
investment pools” [11]. These authors also believe that 
“key areas that a researcher must traverse in the transla-
tional medicine itinerary and in which support structures 
might be developed to improve the chances of success” 
are: “basic science department, innovative technology, 
lead identification development, knowledge of human 
disease, access to patient, clinical science department, 
preclinical development” [11]. More particularly, these 
authors identify the areas of “biomedical research, in-
tellectual property, funding, regulatory agencies, legal 
issues, ethical issues, communication skills, preclinical 
testing, design of preclinical and clinical trials” as those 
in which fundamental “tools and skills” are needed [11].
It is clear from these lists that a multitude of dissimi-
lar skills and competences are needed to accompany 
the transition from bench to bedside and that transla-
tional research is a complex and multidisciplinary affair.
In reverse: from practice to research
While encouraging the transition from research to 
clinical practice, we should not forget the importance 
of the reverse route from clinical practice to research. 
Walley and co-authors noted that “The current model 
for most international health service research is based 
on the assumption that the research community “dis-
covers” solutions and then tries to market them to busy 
decision-makers and practitioners” [12] and stated that 
this approach is “necessary but not sufficient. The aim 
should not be to perfect techniques of feeding results 
to decision-makers, but to start from the perspective 
of the decision-makers even before devising the ques-
tion. This means “getting practice into research” [12]. 
They added that “This approach is not appropriate for 
research into new and untried treatments where effi-
cacy has not been established, but should become the 
norm for operational research, by which we understand 
research into how an intervention is implemented” [12]. 
The reference to operational research generates further 
considerations.
Translational research and operational research
According to The Operational Research Society “Op-
erational research (OR) is the discipline of applying ad-
vanced analytical methods to help make better decisions. 
By using techniques such as problem structuring meth-
ods (sometimes known as “Soft OR”) and mathematical 
modelling to analyse complex situations, operational re-
search gives executives the power to make more effective 
decisions and build more productive systems based on: 
more complete data; consideration of all available op-
tions; careful predictions of outcomes and estimates of 
risk; the latest decision tools and techniques” [13].
The absorption of different methodologies and a mul-
tidisciplinary approach are an enhancement, but care 
should be taken to avoid the risk that definitions and 
categories become loopholes through which to circum-
vent legal obligations or ethical principles. Particularly 
in emerging or developing economies where regula-
tions and controls are less strict, there is a possibility 
that ethical assessments envisaged in regulations may 
be eluded by branding what are effectively clinical trials 
as “operational research” [14].
Requirements and problems
A careful and thorough analysis in “Life cycle of 
translational research for medical interventions” by 
Contopoulos Ioannidis and co-authors identified some 
of the requisites needed to promote translational re-
search. They note in particular that “Discovery of new 
substances and interventions remains essential, but 
proper credit and incentives should be given to accel-
erate the testing of these applications in high-quality, 
unbiased clinical research and the replication of claims 
for effectiveness” [15]. Moreover, “multidisciplinary 
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collaboration with focused targets and involving both 
basic and clinical sciences should be encouraged” [15].
These objectives can be achieved in various ways. 
Ledford, for instance, suggests “4 ways to fix the clini-
cal trial”: “recruit early, skip animals; use models; alter 
course (use adaptive trials)” [5].
The route to a faster transition from research to ap-
plication may be complicated if researchers are not suf-
ficiently familiar with how to address the issues of trans-
lational research: “Many of us would readily claim to be 
translational researchers, but, in reality, very few of us 
know how to navigate the translational pathway – we 
are very comfortable speaking the language of the lab 
but have a quite limited understanding of the plethora 
of legal (how to secure a patent), financial (how to raise 
money to develop our intellectual property), regulatory 
(how to interact with a regulatory agency) and clinical 
(how to recruit subjects for a clinical trial) issues that 
must be considered before we get anywhere near a new 
therapy” [16].
The infrastructures
In 2006 the European Strategy Forum on Research 
Infrastructures (ESFRI) was asked by the European 
Commission to draft a European “road map” for Re-
search Infrastructures (RI) [17]. The report drew at-
tention to the importance of RI in the biomedical 
field, particularly translational research. The Council 
of the European Union subsequently issued a Regula-
tion that creates a single legal foundation to facilitate 
the creation and operation of RI in the form of a Eu-
ropean Research Infrastructure Consortium (ERIC) 
[18], which entered into force on 28 August 2009. 
This specific legal form is designed to facilitate the 
joint establishment and operation of research infra-
structures of European interest.
One of these infrastructures, as we have already seen, 
is EATRIS [19], whose objective is to promote the pro-
cess of translating the results of research into novel 
strategies for the prevention, diagnosis and treatment 
of diseases of particular public health and economic 
importance, which it does through a European network 
of national centres of excellence and high technological 
impact. It assists academic institutions in the process of 
translating research results into new approaches to the 
treatment, prevention and diagnosis of diseases with a 
high socio-economic and health impact and offers in-
dustries the chance to use highly sophisticated and ad-
vanced facilities as part of projects that are of special 
interest from a public health aspect. In other words, 
EATRIS supports translational research projects by sup-
plying an efficient and integrated network of services to 
accompany an untested medicinal product (proof-of-
principle) up to phase I and phase II trials with human 
subjects.
In 2010 the ISS was formally invited by the Ministry 
of Health, in agreement with the Ministry of Educa-
tion, University and Research, to coordinate the Italian 
arms of EATRIS and other infrastructures: the Europe-
an Clinical Research Infrastructures Network (ECRIN) 
[20] and Biobanking and Biomolecular Resources Re-
search Infrastructure (BBMRI) [21].
ETHICAL PROBLEMS
Translational research poses several ethical prob-
lems, many of which are common to all trials involv-
ing human subjects. In the case of translational re-
search, however, these problems differ in both form 
and complexity.
Ethical reviews of research projects often tend to fo-
cus particularly on informed consent and other formal 
aspects, such as the protection of personal data. For ex-
ample, the paragraph headed “Translational research” of 
a manual dealing with the ethical aspects of drawing up 
trial protocols identifies three particular areas of inter-
est: “kinds of public/private collaboration that produce 
serious conflicts of interest”, “reduction in funding for 
undirected basic research” and “personal data protec-
tion” [22]. Naturally, these three are not the only ethical 
questions encountered in the field of translational re-
search; given that it aims to reduce the duration of the 
research phase, one of the key problems is undoubtedly 
that of possible risk to participants.
The risk to participants
A faster transition from research to clinical practice 
could lead to a lowering of safety barriers and an in-
crease in risk.
Solid parameters are therefore necessary to ensure 
appropriate safety levels; clear indications are needed as 
to which laboratory data and which trial models should 
be acceptable as the basis for moving forward from ba-
sic to clinical research.
As a general rule, if there is no adequate evidence of 
benefit for the patient, no more than so-called “mini-
mal” risk should be acceptable. “Minimal risk” has been 
variously defined: one frequently cited definition is to be 
found in the Code of Federal Regulations, which states 
that a risk is “minimal if the “probability and magnitude 
of harm or discomfort anticipated in the research are not 
greater in and of themselves than those ordinarily en-
countered in daily life or during the performance of rou-
tine physical or physiological examinations or tests” [23]. 
Kimmelman and London identify some aspects that 
are particularly important when assessing risks and ben-
efits:
- “ethical judgments about risk, benefit, and patient 
eligibility in clinical trials hinge on predictions about 
harm, therapeutic response, and clinical promise;
- predictions for novel interventions in preclinical 
stages of development suffer from two problems: in-
sufficient attention to threats to validity in preclinical 
research and a reliance on an overly narrow base of evi-
dence that includes only animal and clinical studies of 
the intervention in question (evidential conservatism);
- to improve ethical and scientific decision-making in 
early phase studies, decision-makers should explicitly 
attend to reporting quality and methodological features 
in preclinical experiments that address threats to inter-
nal, construct, and external validity;
- decision-makers should also use evidence that sheds 
light on the reliability of causal claims embedded within 
a proposed trial. This evidence can be gathered from 
outcomes of previous trials involving agents targeting 
related biological pathways (reference classes)” [24].
Ethics in translational rEsEarch
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
65
Expected benefits
Risks and benefits are closely linked, but the objective 
of moving from research to practice – in other words, 
to generalizable knowledge – must not be allowed to 
compromise the cornerstone of trials involving humans, 
namely that the well-being of participants in trials must 
always come before the potential benefit to the com-
munity of an advancement in knowledge. Article 6 of 
the Declaration of Helsinki, for instance, states that: 
“In medical research involving human subjects, the 
well-being of the individual research subject must take 
precedence over all other interests” [25].
Informed consent
The question of direct benefits is one of the issues 
that must be made clear when participants are being 
briefed prior to giving signed consent. As already noted, 
informed consent should never be a mere bureaucratic 
formality.
One of the questions that makes informed consent so 
important in translational research is the need to avoid 
what is known as a “therapeutic misconception”. This 
problem came to light in the 1980s during studies coor-
dinated by Loren Roth [26, 27]. “At its core Therapeu-
tic Misconception (TM) involves patient/participant’s 
failure to recognize how personal care may be compro-
mised by research procedures. (...). (T)his core concept 
of TM can appear in two ways: 1) an incorrect belief 
that the patient/participant’s individualized needs will 
determine assignment to treatment conditions or lead 
to modifications of the treatment regime (TM1) or 2) 
an unreasonable appraisal of the nature or likelihood of 
medical benefit from participation in the study, due to 
misperception of the nature of the research enterprise 
(TM2)” [28].
Possible manipulation for commercial purposes:
translational research in reverse
Informed consent is also important in contrasting 
possible manipulation for commercial purposes. A 
comment published in Nature on a well-publicised in-
cident in Italy concerning a supposed treatment with 
mesenchymal stem cells, warned against “translational 
research in reverse”: “Industry has not yet generated 
conclusively proven medicinal products or major novel 
technologies to better harness the biology of Mesen-
chymal Stem Cells (MSCs). However, commercial in-
terest has profoundly influenced the definition of these 
cells (and of their clinical potential) within the scientific 
community. This is translational medicine in reverse. 
Commercial products have been converted into scien-
tific concepts. It highlights an important dark side of 
the commercialization of science” [29].
Ethical principles and new paradigms
Some authors feel that the ethical challenges posed 
by translational research are so important that it is time 
to formulate “a new conception of clinical research 
ethics” [30], in other words, a paradigm shift. “Medi-
cal research is widely thought to have a fundamentally 
therapeutic orientation, in spite of the fact that clinical 
research is thought to be ethically distinct from medical 
care. We need an entirely new conception of clinical re-
search ethics − one that looks to science instead of the 
doctor-patient relationship” [31].
The statement that we need to “(look) to science 
instead of the doctor-patient relationship” may seem 
puzzling, and rightly so. It must not be allowed to turn 
the foundation of research ethics on its head: as already 
noted, the interests of the participants in trials must al-
ways have priority over those of the community in terms 
of improved knowledge.
As mentioned above, the problems posed by ethics in 
translational research are common to much of research 
with human subjects. There is thus no need for a new 
ethical approach: the principles established for biomed-
ical ethics are amply sufficient.
There is an increasing tendency to link the terms 
“ethics” and “bioethics” with adjectives, as in “prag-
matic bioethics” [28], “applied bioethics” [32] and 
even “synthetic bioethics” [33] (with reference to 
“synthetic biology” [34]), as well as “translational 
ethics” [35]. The latter expression is somewhat baf-
fling if it is intended to reflect the proposal (typical 
of sociobiology, for instance) [36] to found ethics on 
facts, in other words to “translate” facts to principles. 
Instead we should encourage “translational ethics” 
as meaning the translation of knowledge to practice: 
“Much as translational research attempts to connect 
the laboratory scientist’s work to its implications for 
patient care, translational ethics focuses on bringing 
ethical scholarship into the sphere of personal and 
public action” [35].
While translational research does not need to investi-
gate novel routes to ethical reviews, it does perhaps call 
for the application of logic to identify the right proce-
dures by applying the basic ethical values of research 
with human subjects to the specific context.
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